Epidiolex 100 mg/mL Oral Solution ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
140	Dorabe syndrome	1
144	Lennox-Gastaut syndrome	1

140. Dorabe syndrome

---

Clinical trials : 116 /  Drugs : 65 - (DrugBank : 17) / Drug target genes : 50 - Drug target pathways : 64

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05485831 (ClinicalTrials.gov)	April 2023	29/7/2022	Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY	Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	Lennox Gastaut Syndrome;Dravet Syndrome	Drug: Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Evidilya S.r.l.	Not yet recruiting	6 Years	17 Years	All	70		Italy

144. Lennox-Gastaut syndrome

---

Clinical trials : 111 /  Drugs : 72 - (DrugBank : 14) / Drug target genes : 49 - Drug target pathways : 61

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05485831 (ClinicalTrials.gov)	April 2023	29/7/2022	Epidyolex® in Lennox Gastaut and Dravet Syndrome: an Observational Study in ITALY	Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS)	Lennox Gastaut Syndrome;Dravet Syndrome	Drug: Epidiolex 100 mg/mL Oral Solution	Jazz Pharmaceuticals	Evidilya S.r.l.	Not yet recruiting	6 Years	17 Years	All	70		Italy